Most Common Adverse Events6
The most frequently reported adverse reactions (≥25%) in clinical trials were dizziness, nausea, confusional state, and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuation of PRIALT for adverse reactions. Adverse reactions during the slow titration placebo-controlled trial are summarized in the table below.
Incidence of adverse reactions in the slow titration placebo-controlled trial by percent (events that occurred in ≥5% of patients and more commonly with PRIALT than with placebo)